Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic AcidDaiichi Sankyo2024-11-25 15:22:25Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With
-
New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groupsDaiichi Sankyo2024-08-06 16:38:16New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse
-
Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in EuropeDaiichi Sankyo2024-08-06 16:38:29Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in Europe
-
First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular riskDaiichi Sankyo2024-08-06 16:38:40First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼,
-
CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose combination tablet as treatments for hypercholesterolaemia and significantly reducing cardiovascular eventsDaiichi Sankyo2024-03-25 09:37:57CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose
-
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending LitigationDaiichi Sankyo2024-01-03 13:44:14Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including
-
Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV eventsDaiichi Sankyo2022-12-08 10:41:45Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative
-
Latest simulation analyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid lowering treatment algorithm might help more patients achieve LDL-C recommended goalsDaiichi Sankyo2022-09-06 16:43:43Latest simulation analyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid
-
New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations with atrial fibrillation (AF)Daiichi Sankyo2022-09-06 16:40:26New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations
-
Daiichi Sankyo Europe highlights need to address the perception and classification of CVD risk with data presentations at EAS 2022Daiichi Sankyo2022-05-24 17:09:00Daiichi Sankyo Europe highlights need to address the perception and classification of CVD risk with data
